Abstract:In HIV-1 infection, many antibodies (Abs) are elicited to Envelope (Env) epitopes that are conformationally masked in the native trimer and are only available for antibody recognition after the trimer binds host cell CD4. Among these are epitopes within the Co-Receptor Binding Site (CoRBS) and the constant region 1 and 2 (C1-C2 or cluster A region). In particular, C1-C2 epitopes map to the gp120 face interacting with gp41 in the native, "closed" Env trimer present on HIV-1 virions or expressed on HIV-1-infected cells. Antibodies targeting this region are therefore nonneutralizing and their potential as mediators of antibody-dependent cellular cytotoxicity (ADCC) of HIV-1-infected cells diminished by a lack of available binding targets. Here, we present the design of Ab-CD4 chimeric proteins that consist of the Ab-IgG1 of a CoRBS or cluster A specificity to the extracellular domains 1 and 2 of human CD4. Our Ab-CD4 hybrids induce potent ADCC against infected primary CD4+ T cells and neutralize tier 1 and 2 HIV-1 viruses. Furthermore, competition binding experiments reveal that the observed biological activities rely on both the antibody and CD4 moieties, confirming their cooperativity in triggering conformational rearrangements of Env. Our data indicate the utility of these Ab-CD4 hybrids as antibody therapeutics that are effective in eliminating HIV-1 through the combined mechanisms of neutralization and ADCC. This is also the first report of single-chain-Ab-based molecules capable of opening "closed" Env trimers on HIV-1 particles/infected cells to expose the cluster A region and activate ADCC and neutralization against these nonneutralizing targets. IMPORTANCE Highly conserved epitopes within the coreceptor binding site (CoRBS) and constant region 1 and 2 (C1-C2 or cluster A) are only available for antibody recognition after the HIV-1 Env trimer binds host cell CD4; therefore, they are not accessible on virions and infected cells, where the expression of CD4 is downregulated. Here, we have developed new antibody fusion molecules in which domains 1 and 2 of soluble human CD4 are linked with monoclonal antibodies of either the CoRBS or cluster A specificity. We optimized the conjugation sites and linker lengths to allow each of these novel bispecific fusion molecules to recognize native "closed" Env trimers and induce the structural rearrangements required for exposure of the epitopes for antibody binding. Our in vitro functional testing shows that our Ab-CD4 molecules can efficiently target and eliminate HIV-1-infected cells through antibody-dependent cellular cytotoxicity and inactivate HIV-1 virus through neutralization.

ELDKWA-epitope-specific monoclonal antibodies inhibit HIV env-mediated syncytium formation.

Characterization of Antibody Responses Against the 2F5 Epitope ELDKWA sing HIV-1 Env-Mediated Membrane Fusion and Neutralization Assays

A predefined epitope-specific monoclonal antibody recognizes ELDEWA-epitope just presenting on gp41 of HIV-1 O clade.

Short Communication: in VitroSynergy Between Peptides or Neutralizing Antibodies Targeting the N- and C-Terminal Heptad Repeats of HIV Type 1 Gp41

ELNKWA-epitope Specific Antibodies Induced by Epitope-Vaccine Recognize ELDKWA- and Other Two Neutralizing-Resistant Mutated Epitopes on HIV-1 Gp41

Neutralization of HIV-1 Primary Isolate by ELDKWA-specific Murine Monoclonal Antibodies.

Monoclonal Antibodies Recognizing HIV-1 Gp41 Could Inhibit Env-Mediated Syncytium Formation

Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41.

Epitope-Vaccine Induces High Levels of Eldkwa-Epitope-Specific Neutralizing Antibody

Induction of High Level of Specific Antibody Response to the Neutralizing Epitope ELDKWA on HIV-1 Gp41 by Peptide-Vaccine☆

Predefined GPGRAFY-Epitope-Specific Monoclonal Antibodies with Different Activities for Recognizing Native HIV-1 Gp120

Induction of High Levels of Antibodies Recognizing the Neutralizing Epitope Eldkwa and the D- or K-Position-Mutated Epitopes by Candidate Epitope Vaccines Against Hiv-1

A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope.

Across Functional Boundaries: Making Nonneutralizing Antibodies To Neutralize HIV-1 and Mediate Fc-Mediated Effector Killing of Infected Cells

Epitope-focused Immunogens Against the CD4-binding Site of HIV-1 Envelope Protein Induce Neutralizing Antibodies Against Auto- and Heterologous Viruses

Multifaceted Consequences of Anti-Gp41 Monoclonal Antibody 2F5 Binding to HIV Type 1 Virions.

Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor.

F(ab′)2 Fragment of a Gp41 NHR-trimer-induced IgM Monoclonal Antibody Neutralizes HIV-1 Infection and Blocks Viral Fusion by Targeting the Conserved Gp41 Pocket

Identification of Critical Antibody-Binding Sites in the HIV-1 Gp41 Six-Helix Bundle Core As Potential Targets for HIV-1 Fusion Inhibitors

Mucosal Antibodies Induced by Tandem Repeat of 2f5 Epitope Block Transcytosis of Hiv-1

Fusion Peptide of HIV-1 As a Site of Vulnerability to Neutralizing Antibody